Pfizer's Sandwich sale talks fall through; Servier trial stopped for constitutional appeal;

 @FiercePharma: J&J's Simponi beat placebo at fighting colitis symptoms, study finds. Possible new use with 700K cases, WSJ says. More |  Follow @FiercePharma

> Pfizer ($PFE) failed to reach a deal to sell its Sandwich, U.K., R&D site after months of exclusive talks with a buyer; the company is now entertaining other interested parties. News

> Servier and several company executives won a temporary reprieve from a criminal trial in Nanterre, France, when a higher court agreed to consider an appeal on constitutional grounds. Report

> Merck ($MRK) won a label update for its HIV drug Isentress to include study data showing long-term viral suppression after 156 weeks of treatment with Isentress in combination with efavirenz. Article

> PhRMA delivered a wish list to Washington, along with a warning that the industry might get more support from other countries. Story

> Johnson & Johnson's ($JNJ) anti-inflammatory drug Simponi improved symptoms in a majority of patients with ulcerative colitis in a study, in results that could support a new indication for the Remicade follow-up drug. Item

> Janssen's Nucynta drug relieved pain in patients with diabetic peripheral neuropathy, the company said, after a 12-week study. News

> Counterfeits and poorly made drugs are interfering with malaria-eradication efforts, NIH says, after finding one-third of drug samples from Southeast Asia and Africa didn't meet standards. More

Biotech News

 @FierceBiotech: New strategy from researchers at Penn State reactivates genes to suppress cancer. More | Follow @FierceBiotech

 @JohnCFierce: Pfizer sent me their take on tafamidis just now. No retreat, no surrender. Story | Follow @JohnCFierce

 @RyanMFierce: Survey says building "electronic" trials is painfully slow, but that's true for most all clinical trials. More | Follow @RyanMFierce

> Takeda shutters Bay Area R&D shop in California shakeup. Story

> Biotechs raise new VC rounds to back inhalable drugs, antimicrobials. Article

> Lilly posts clean safety data on PhIII diabetes blockbuster hopeful. More

> TheStreet: A roundup of the top drug studies left in 2012. Report

Medical Devices News

 @FierceMedDev: Medtronic Q4 earnings jumped just 3%. More | Follow @FierceMedDev

 @MarkHFierce: Please submit your nominations soon for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Accuray inks deal with cancer research center. News

> Device industry: Purpose of 510(k) changes remains unclear. Article

> Consumer group demands major change in user fee bill. Item

Pharma Manufacturing News

> FDA inspectors cite problems at Impax California plant. News

> Funding would allow FDA to target more foreign plants. More

> Chinese court favors J&J in distribution fight. Article

Biotech Research News

> Malaria's genetic secrets open door to new drug targets. Story

> Celery extract shrinks difficult breast cancer tumor in mouse trials. Article

> New strategy reactivates genes to suppress cancer. Report

> Researchers find novel way to treat anxiety. More

> Gene therapy = fountain of youth in mice. Item

And Finally... Forty-three Catholic institutions have sued the Obama Administration over a mandate requiring employers to pay for contraceptives. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.